Table 2. Clinical characteristics of the tertiles based on data 6 months postdischarge.
| Group 1 | Group 2 | Group 3 | p value (Group1 vs 2, 1 vs 3,2 vs 3) | |
|---|---|---|---|---|
| Patients (N) | 64 | 72 | 72 | |
| Estimated 5-year mortality, % | 8.2 ±2.2 | 18.5± 4.8 | 43.0 ±12.1 | |
| Age | 62.6 ± 11.9 | 69.6± 10.3 | 72.7± 7.0 | <0.001, <0.001, 0.177 |
| Sex (male) | 37 (57.8%) | 47 (65.3%) | 46 (63.9%) | 0.636 |
| Ischemic heart disease | 28 (43.8%) | 32 (44.4%) | 29 (40.3%) | 0.879 |
| Pharmacotherapy | ||||
| ACE inhibitors | 35 (54.7%) | 51 (70.8%) | 51 (70.8%) | 0.086 |
| ARBs | 46 (71.9%) | 49 (68.1%) | 39 (54.2%) | 0.074 |
| β-blockers | 36 (56.3%) | 29 (40.3%) | 27 (37.5%) | 0.065 |
| MRAs | 31 (48.4%) | 27 (37.5%) | 24 (33.3%) | 0.189 |
| NYHA functional class (I/II/III/IV) | 24/38/2/0 | 13/42/17/0 | 3/6/62/1 | <0.001, <0.001, <0.001 |
| MIBG scintigraphy | ||||
| % denervation | 41.9± 11.9 | 52.3± 12.9 | 59.4± 13.9 | <0.001, <0.001, 0.004 |
| HMR | 1.96 ±0.18 | 1.73± 0.18 | 1.60± 0.24 | <0.001, <0.001, <0.001 |
| WR | 36.8± 9.56 | 44.2± 11.0 | 53.2± 14.0 | <0.001, <0.001, <0.001 |
| Echocardiography | ||||
| LVEDV, mL | 148± 40.1 | 174± 52.8 | 181 ± 50.0 | 0.005, <0.001, 0.628 |
| LVESV, mL | 85.6± 34.9 | 112± 50.7 | 125± 52.1 | 0.003, <0.001, 0.234 |
| LVEF, % | 43.5± 9.03 | 37.4 ±9.74 | 32.8± 10.8 | 0.001, <0.001, 0.017 |
ACE, angiotensin-converting enzyme; ARBs, angiotensin-receptor blockers; HMR, heart-to-mediastinum ratio; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MIBG, metaiodobenzylguanidine; MRAs, mineralocorticoid receptor antagonists; NYHA, New York Heart Association; WR, washout rate.
P value notes the value of each group by multiple comparisons when P value of the comparison of three groups is <0.05.